stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
16.94 | 22.37 | 23.76 | 38.51 |
Net Debt/EBITDA |
9.94 | 9.61 | 10.56 | 17.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.76 | 0.74 | 0.80 | |
Capex/Depreciation |
0.10 | 0.10 | 0.18 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.49) | (0.50) | (0.43) | (0.53) | |
Cash per Share |
7.92 | 7.39 | 7.05 | 13.89 | |
Shareholders Equity per Share |
11.05 | 10.35 | 8.82 | 17.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.05 | 10.35 | 8.82 | 17.73 | |
Free Cash Flow |
(21.70) | (22.66) | (23.65) | (33.14) | |
Working Capital |
334.20 | 328.48 | 378.62 | 861.59 | |
Capital Expenditures |
(0.10) | (0.06) | (0.07) | 0.00 | |
Net Current Asset Value |
332.70 | 327.17 | 377.49 | 859.71 | |
| Other line items | |||||
Quick Ratio |
16.65 | 21.92 | 23.38 | 38.03 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.49) | (0.50) | (0.43) | (0.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.36 | 6.82 | 5.51 | 6.37 | |
Average Assets |
461.67 | 442.32 | 440.80 | 748.41 | |
Average Common Equity |
411.65 | 424.14 | 422.79 | 726.16 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026